E-ISSN 2577-5669
 

Research Article 


Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation

Hajer Sh*. Ali, Nawal A. Rajab.

Abstract
The main aim of this research work was the development and evaluation of polymeric nanoparticle for the bioavailability improvement of Ebastine (EBT) to treat allergic condition. EBT is a piperidine derivative that binds preferentially to peripheral H1 receptors and is a long-acting, non-sedating second-generation histamine receptor antagonist. It is practically insoluble in water (class II, according to BCS). This work aims to formulate and adjust Ebastine polymeric nanoparticles to improve the EBT solubility as well as dissolution rate. For the synthesis of PNPs, the solvent evaporation technique was used, and three different types of stabilizer that used (HPMC E5, Soluplus, tween 80). The particle size analysis indicated that the optimized formula EBT 9 had a reduced nanoparticulate size of 42 nm, with a 90 percent increase in in-vitro dissolution profile compared to 17 percent for the comparison Ebastine powder in 0.1 N HCl media (pH 1.2). As a result, polymeric nanoparticles formulation of weakly water soluble EBS greatly improved the drug's dissolving rate and increased its solubility.

Key words: Polymeric nanoparticles (PNPs), Evaluation, Preparation, Delivery.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Hajer Sh*. Ali
Articles by Nawal A. Rajab
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Ali HS, Rajab NA. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. J Complement Med Res. 2023; 14(1): 16-20. doi:10.5455/jcmr.2023.14.01.03


Web Style

Ali HS, Rajab NA. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. https://www.jocmr.com/?mno=71933 [Access: May 26, 2023]. doi:10.5455/jcmr.2023.14.01.03


AMA (American Medical Association) Style

Ali HS, Rajab NA. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. J Complement Med Res. 2023; 14(1): 16-20. doi:10.5455/jcmr.2023.14.01.03



Vancouver/ICMJE Style

Ali HS, Rajab NA. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. J Complement Med Res. (2023), [cited May 26, 2023]; 14(1): 16-20. doi:10.5455/jcmr.2023.14.01.03



Harvard Style

Ali, H. S. & Rajab, . N. A. (2023) Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. J Complement Med Res, 14 (1), 16-20. doi:10.5455/jcmr.2023.14.01.03



Turabian Style

Ali, Hajer Sh., and Nawal A. Rajab. 2023. Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. Journal of Complementary Medicine Research, 14 (1), 16-20. doi:10.5455/jcmr.2023.14.01.03



Chicago Style

Ali, Hajer Sh., and Nawal A. Rajab. "Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation." Journal of Complementary Medicine Research 14 (2023), 16-20. doi:10.5455/jcmr.2023.14.01.03



MLA (The Modern Language Association) Style

Ali, Hajer Sh., and Nawal A. Rajab. "Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation." Journal of Complementary Medicine Research 14.1 (2023), 16-20. Print. doi:10.5455/jcmr.2023.14.01.03



APA (American Psychological Association) Style

Ali, H. S. & Rajab, . N. A. (2023) Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation. Journal of Complementary Medicine Research, 14 (1), 16-20. doi:10.5455/jcmr.2023.14.01.03